These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38018304)

  • 81. Superselective Transarterial Chemoembolization for Unresectable or "Ablation Unsuitable" Hepatocellular Carcinoma in the Caudate Lobe: A Real World, Single-Center Retrospective Study.
    Yan L; Ren Y; Qian K; Kan X; Zhang H; Chen L; Liang B; Zheng C
    Front Oncol; 2021; 11():678847. PubMed ID: 34778023
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.
    Chauhan N; Bukovcan J; Boucher E; Cosgrove D; Edeline J; Hamilton B; Kulik L; Master F; Salem R
    JMIR Res Protoc; 2018 Aug; 7(8):e11234. PubMed ID: 30111528
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma.
    Shao W; Li C; Tang J; Song J; Li Z; Sun J; Xu Y; Zheng Z; Cao J; Zhang L
    Cancer Manag Res; 2019; 11():9863-9869. PubMed ID: 31819623
    [TBL] [Abstract][Full Text] [Related]  

  • 85. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
    Kirner A; Mayer-Mokler A; Reinhardt C
    Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Transarterial chemoembolization combined donafenib with/without PD-1 for unresectable HCC in a multicenter retrospective study.
    Li H; Wang J; Zhang G; Kuang D; Li Y; He X; Xing C; Wang Y; Shi M; Han X; Ren J; Duan X
    Front Immunol; 2023; 14():1277329. PubMed ID: 38090566
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor.
    Xie QY; Huang LP; Gao FW; Liu DQ; Wang X; Jiang KY; Gong J; Zhao X; Gao BJ; Lei ZH
    Front Pharmacol; 2022; 13():965770. PubMed ID: 36339553
    [No Abstract]   [Full Text] [Related]  

  • 88. CT-guided
    Chen Z; Fu X; Qiu Z; Mu M; Jiang W; Wang G; Zhong Z; Qi H; Gao F
    Radiol Oncol; 2023 Mar; 57(1):127-139. PubMed ID: 36942903
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up.
    Ou HY; Wu YN; Yu CY; Chen CL; Hsu HW; Weng CC; Leung-Chit Tsang L; Huang TL; Tong YS; Lim WX; Cheng YF
    J Vasc Interv Radiol; 2020 Nov; 31(11):1784-1791. PubMed ID: 33023805
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A prospective phase 2 multicenter study for the efficacy of radiation therapy following incomplete transarterial chemoembolization in unresectable hepatocellular carcinoma.
    Choi C; Koom WS; Kim TH; Yoon SM; Kim JH; Lee HS; Nam TK; Seong J
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1051-60. PubMed ID: 25303890
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study.
    Xia WL; Zhao XH; Guo Y; Cao GS; Wu G; Fan WJ; Yao QJ; Xu SJ; Guo CY; Hu HT; Li HL
    Front Oncol; 2022; 12():961394. PubMed ID: 36249011
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.
    Cheng AL; Thongprasert S; Lim HY; Sukeepaisarnjaroen W; Yang TS; Wu CC; Chao Y; Chan SL; Kudo M; Ikeda M; Kang YK; Pan H; Numata K; Han G; Balsara B; Zhang Y; Rodriguez AM; Zhang Y; Wang Y; Poon RT
    Hepatology; 2016 Sep; 64(3):774-84. PubMed ID: 27082062
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma.
    Ryoo BY; Palmer DH; Park SR; Rimassa L; Debashis Sarker ; Daniele B; Steinberg J; López B; Lim HY
    Clin Drug Investig; 2021 Sep; 41(9):795-808. PubMed ID: 34351608
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
    JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Super-selective transarterial chemoembolization of hepatocellular carcinoma with doxorubicin-eluting beads sized 40-75 microns: assessment of efficacy and safety.
    Ballı HT; Aikimbaev K
    Diagn Interv Radiol; 2020 Sep; 26(5):482-487. PubMed ID: 32815520
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma.
    Tsuchiya N; Yoshikawa T; Fujinami N; Saito K; Mizuno S; Sawada Y; Endo I; Nakatsura T
    Oncoimmunology; 2017; 6(10):e1346764. PubMed ID: 29123959
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis.
    Qin J; Huang Y; Zhou H; Yi S
    Front Oncol; 2022; 12():807102. PubMed ID: 35463356
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Peptide vaccines get an OS update.
    Zacharias M; Springer S
    Nat Chem Biol; 2024 May; 20(5):549-550. PubMed ID: 38580838
    [No Abstract]   [Full Text] [Related]  

  • 99. Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma.
    Yoshimaru Y; Nagaoka K; Tanaka K; Narahara S; Inada H; Kurano S; Tokunaga T; Iio E; Watanabe T; Setoyama H; Tateyama M; Yoshida K; Tsunoda T; Nakamura Y; Tanaka M; Sasaki Y; Tanaka Y
    Hepatol Res; 2024 May; 54(5):451-464. PubMed ID: 38018304
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
    Masuzawa T; Fujiwara Y; Okada K; Nakamura A; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Osawa R; Takeda K; Yoshida K; Tsunoda T; Nakamura Y; Mori M; Doki Y
    Int J Oncol; 2012 Oct; 41(4):1297-304. PubMed ID: 22842485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.